LT3564258T - Karkasiniai domeniniai baltymai fibronektino pagrindu, kurie jungiasi su miostatinu - Google Patents
Karkasiniai domeniniai baltymai fibronektino pagrindu, kurie jungiasi su miostatinuInfo
- Publication number
- LT3564258T LT3564258T LTEP19162848.6T LT19162848T LT3564258T LT 3564258 T LT3564258 T LT 3564258T LT 19162848 T LT19162848 T LT 19162848T LT 3564258 T LT3564258 T LT 3564258T
- Authority
- LT
- Lithuania
- Prior art keywords
- myostatin
- bind
- domain proteins
- based scaffold
- scaffold domain
- Prior art date
Links
- 102100037362 Fibronectin Human genes 0.000 title 1
- 108010067306 Fibronectins Proteins 0.000 title 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 title 1
- 108010056852 Myostatin Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Pathology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261700697P | 2012-09-13 | 2012-09-13 | |
US201361780005P | 2013-03-13 | 2013-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3564258T true LT3564258T (lt) | 2021-08-25 |
Family
ID=49253416
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP13767190.5T LT2895503T (lt) | 2012-09-13 | 2013-09-12 | Karkasiniai domeniniai baltymai fibronektino pagrindu, kurie sąveikauja su miostatinu |
LTEP19162848.6T LT3564258T (lt) | 2012-09-13 | 2013-09-12 | Karkasiniai domeniniai baltymai fibronektino pagrindu, kurie jungiasi su miostatinu |
LTEP20206702.1T LT3835310T (lt) | 2012-09-13 | 2013-09-12 | Fibronektino pagrindo karkaso domeno baltymai, kurie rišasi prie miostatino |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP13767190.5T LT2895503T (lt) | 2012-09-13 | 2013-09-12 | Karkasiniai domeniniai baltymai fibronektino pagrindu, kurie sąveikauja su miostatinu |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP20206702.1T LT3835310T (lt) | 2012-09-13 | 2013-09-12 | Fibronektino pagrindo karkaso domeno baltymai, kurie rišasi prie miostatino |
Country Status (32)
Country | Link |
---|---|
US (8) | US8933199B2 (lt) |
EP (3) | EP3564258B1 (lt) |
JP (2) | JP6346895B2 (lt) |
KR (3) | KR102424590B1 (lt) |
CN (2) | CN104768969B (lt) |
AU (2) | AU2013315482B2 (lt) |
BR (1) | BR112015005466B1 (lt) |
CA (1) | CA2884730C (lt) |
CL (1) | CL2015000500A1 (lt) |
DK (2) | DK2895503T3 (lt) |
EA (1) | EA033536B1 (lt) |
ES (2) | ES2879387T3 (lt) |
HK (1) | HK1212717A1 (lt) |
HR (2) | HRP20190845T1 (lt) |
HU (2) | HUE054699T2 (lt) |
IL (3) | IL270110B (lt) |
LT (3) | LT2895503T (lt) |
MX (2) | MX366666B (lt) |
MY (2) | MY189682A (lt) |
NZ (1) | NZ628446A (lt) |
PE (1) | PE20150954A1 (lt) |
PH (1) | PH12015500397B1 (lt) |
PL (2) | PL3564258T3 (lt) |
PT (2) | PT2895503T (lt) |
RS (2) | RS62009B1 (lt) |
SG (3) | SG10201701970TA (lt) |
SI (2) | SI3564258T1 (lt) |
TN (1) | TN2015000086A1 (lt) |
TW (2) | TWI633117B (lt) |
UY (1) | UY35027A (lt) |
WO (1) | WO2014043344A1 (lt) |
ZA (1) | ZA201501457B (lt) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4001409A1 (en) | 2006-03-31 | 2022-05-25 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
EP3521311A1 (en) | 2008-04-11 | 2019-08-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP3091028A1 (en) | 2010-05-26 | 2016-11-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
CA2819356C (en) | 2010-11-30 | 2023-01-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
PT2697257T (pt) | 2011-04-13 | 2016-12-28 | Bristol Myers Squibb Co | Proteínas de fusão fc compreendendo novos ligantes ou arranjos |
KR20230110836A (ko) | 2012-08-24 | 2023-07-25 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc영역 개변체 |
US11236168B2 (en) | 2012-08-24 | 2022-02-01 | Chugai Seiyaku Kabushiki Kaisha | Mouse FcγammaRII-specific Fc antibody |
CN104768969B (zh) | 2012-09-13 | 2021-04-16 | 百时美施贵宝公司 | 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白 |
ES2715710T3 (es) | 2013-01-25 | 2019-06-05 | Shire Human Genetic Therapies | Folistatina en el tratamiento de la distrofía muscular de Duchenne |
WO2014120891A2 (en) | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
ES2689372T3 (es) | 2013-02-06 | 2018-11-13 | Bristol-Myers Squibb Company | Proteínas de dominio de fibronectina tipo III con solubilidad mejorada |
EP3617220B1 (en) | 2013-02-12 | 2021-03-24 | Bristol-Myers Squibb Company | High ph protein refolding methods |
EP2982689B1 (en) | 2013-04-02 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
CA2911514A1 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
KR102472862B1 (ko) | 2014-03-20 | 2022-12-05 | 브리스톨-마이어스 스큅 컴퍼니 | 혈청 알부민-결합 피브로넥틴 유형 iii 도메인 |
CA2943228C (en) | 2014-03-20 | 2023-03-14 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
US10016394B2 (en) | 2014-04-16 | 2018-07-10 | The Scripps Research Institute | PPARG modulators for treatment of osteoporosis |
WO2016018917A2 (en) | 2014-07-28 | 2016-02-04 | The Regents Of The University Of Califoria | Compositions and methods of making polymerized nucleic acids |
WO2016023036A1 (en) * | 2014-08-08 | 2016-02-11 | The Regents Of The University Of California | High density peptide polymers |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
TWI758928B (zh) | 2014-11-21 | 2022-03-21 | 美商必治妥美雅史谷比公司 | 抗cd73抗體及其用途 |
DK3221346T3 (da) | 2014-11-21 | 2020-10-12 | Bristol Myers Squibb Co | Antistoffer omfattende modificerede konstante områder af tungkæden |
JP6701217B2 (ja) | 2014-11-25 | 2020-05-27 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 生物学的製剤の18f−放射性標識方法および組成物 |
CN114591420A (zh) | 2014-11-25 | 2022-06-07 | 百时美施贵宝公司 | 用于成像的新型pd-l1结合多肽 |
NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
JP6180663B2 (ja) | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Tigitに対する抗体 |
EA201791754A1 (ru) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
US10993993B2 (en) * | 2015-05-28 | 2021-05-04 | Immunoforge Co., Ltd. | Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist |
WO2016196228A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
WO2017004016A1 (en) | 2015-06-29 | 2017-01-05 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
WO2017040332A1 (en) * | 2015-08-28 | 2017-03-09 | University Of Massachusetts | Quantifying net axonal transport in motor neuron pathologies |
WO2017083224A1 (en) | 2015-11-09 | 2017-05-18 | Bristol-Myers Squibb Company | Methods to manipulate quality attributes of polypeptides produced in cho cells |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
SG10201913033UA (en) | 2016-03-04 | 2020-03-30 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
AU2016394956B2 (en) | 2016-03-04 | 2024-02-08 | The Rockefeller University | Antibodies to CD40 with enhanced agonist activity |
RU2613420C1 (ru) * | 2016-04-13 | 2017-03-16 | Сергей Михайлович Юдин | Рекомбинантный белок Мио-ГСД, способ его получения, инъекционный препарат для повышения мышечной массы сельскохозяйственных животных, птицы и животных семейства псовых, а также способ использования препарата |
US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
CN109071613A (zh) | 2016-05-11 | 2018-12-21 | 通用电气医疗集团生物工艺研发股份公司 | 分离基质 |
US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
WO2017194593A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
US11708390B2 (en) | 2016-05-11 | 2023-07-25 | Cytiva Bioprocess R&D Ab | Method of storing a separation matrix |
JP7016323B2 (ja) | 2016-06-01 | 2022-02-21 | ブリストル-マイヤーズ スクイブ カンパニー | Pd-l1結合ポリペプチドを用いるpet造影 |
US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
RU2757394C2 (ru) * | 2016-08-03 | 2021-10-14 | Нексткьюр, Инк. | Композиции и способы для модуляции передачи сигнала lair |
CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
TW201821099A (zh) | 2016-12-05 | 2018-06-16 | 日商大塚製藥股份有限公司 | 肌肉萎縮抑制組成物 |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
TW201842929A (zh) * | 2017-05-03 | 2018-12-16 | 美商必治妥美雅史谷比公司 | 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物 |
MX2019013132A (es) | 2017-05-25 | 2020-01-27 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas. |
JP7284759B2 (ja) | 2017-12-27 | 2023-05-31 | ブリストル-マイヤーズ スクイブ カンパニー | 抗cd40抗体およびその使用 |
US11401331B2 (en) * | 2018-01-25 | 2022-08-02 | I-Mab Biopharma Us Limited | Anti-PD-L1 antibody and IL-7 fusions |
CN108593615A (zh) * | 2018-05-02 | 2018-09-28 | 浠思(上海)生物技术有限公司 | 利用htrf一步法筛选pd1/pd-l1阻断剂的方法 |
JP7051656B2 (ja) | 2018-09-28 | 2022-04-11 | 三菱重工コンプレッサ株式会社 | タービンステータ、蒸気タービン、及び仕切板 |
KR20210092769A (ko) | 2018-11-16 | 2021-07-26 | 브리스톨-마이어스 스큅 컴퍼니 | 항-nkg2a 항체 및 그의 용도 |
EP3887397A1 (en) | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
EP4118118A1 (en) | 2020-03-09 | 2023-01-18 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
US11566346B2 (en) * | 2020-06-25 | 2023-01-31 | Philip David Rodley | Protein scaffold |
WO2023196818A1 (en) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Genetic complementation compositions and methods |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US6018030A (en) | 1986-11-04 | 2000-01-25 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
US5589173A (en) | 1986-11-04 | 1996-12-31 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
US5641648A (en) | 1986-11-04 | 1997-06-24 | Protein Polymer Technologies, Inc. | Methods for preparing synthetic repetitive DNA |
US5770697A (en) | 1986-11-04 | 1998-06-23 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
US5514581A (en) | 1986-11-04 | 1996-05-07 | Protein Polymer Technologies, Inc. | Functional recombinantly prepared synthetic protein polymer |
US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
US5792742A (en) | 1991-06-14 | 1998-08-11 | New York University | Fibrin-binding peptide fragments of fibronectin |
WO2002081494A1 (en) | 2001-03-26 | 2002-10-17 | Sirna Therapeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
WO1994017097A1 (en) | 1993-01-19 | 1994-08-04 | Regents Of The University Of Minnesota | Synthetic fibronectin fragments as inhibitors of retroviral infections |
US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
US6673534B1 (en) | 1995-10-26 | 2004-01-06 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
US20030074680A1 (en) | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
US7332575B2 (en) | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
PT971946E (pt) | 1997-01-21 | 2006-11-30 | Gen Hospital Corp | Selecção de proteínas utilizando fusões arn-proteína |
AU6274298A (en) | 1997-02-05 | 1998-08-25 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-8 |
US7749498B2 (en) | 1997-03-10 | 2010-07-06 | Genentech, Inc. | Antibodies for inhibiting blood coagulation and methods of use thereof |
ES2301198T3 (es) | 1997-06-12 | 2008-06-16 | Novartis International Pharmaceutical Ltd. | Polipeptidos artificiales de anticuerpos. |
WO1999051773A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
DE69941116D1 (de) | 1998-05-06 | 2009-08-27 | Metamorphix Inc | G von gdf-8 |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
AU775076B2 (en) | 1998-12-10 | 2004-07-15 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
JP2003528632A (ja) | 2000-03-31 | 2003-09-30 | インスティティ・パスツール | 血管内皮成長因子(vegf)−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法 |
CA2416219C (en) | 2000-07-11 | 2016-10-11 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
AU1325102A (en) | 2000-10-16 | 2002-04-29 | Phylos Inc | Protein scaffolds for antibody mimics and other binding proteins |
US7598352B2 (en) | 2000-11-17 | 2009-10-06 | University Of Rochester | Method of identifying polypeptide monobodies which bind to target proteins and use thereof |
US7556925B2 (en) | 2001-04-04 | 2009-07-07 | University Of Rochester | ανβ3 integrin-binding polypeptide monobodies and their use |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
WO2003104418A2 (en) | 2002-06-06 | 2003-12-18 | Research Corporation Technologies, Inc. | Reconstituted polypeptides |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
ES2466716T3 (es) | 2002-11-08 | 2014-06-11 | Ablynx N.V. | Anticuerpos de un solo dominio estabilizados |
TW200531979A (en) | 2003-12-05 | 2005-10-01 | Compound Therapeutics Inc | Inhibitors of type 2 vascular endothelial growth factor receptors |
US20080220049A1 (en) | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
NZ548612A (en) | 2004-02-09 | 2009-11-27 | Human Genome Sciences Inc | Albumin fusion proteins comprising tandem GLP-1 |
US20070178095A1 (en) | 2004-03-23 | 2007-08-02 | Eli Lilly And Company | Anti-myostatin antibodies |
WO2005118646A2 (en) | 2004-04-26 | 2005-12-15 | Centocor, Inc. | Epitope directed selection of antibodies to murine tissue factor |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
CA2582374A1 (en) | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
TW200724548A (en) | 2005-04-25 | 2007-07-01 | Pfizer | Antibodies to myostatin |
EP2407486B1 (en) | 2005-08-19 | 2017-11-22 | Wyeth LLC | Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders |
CA2624976A1 (en) | 2005-10-06 | 2007-04-19 | Eli Lilly And Company | Anti-myostatin antibodies |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
EP1968621A2 (en) | 2005-12-06 | 2008-09-17 | Amgen Inc. | Uses of myostatin antagonists |
US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
JP5058261B2 (ja) | 2006-09-05 | 2012-10-24 | イーライ リリー アンド カンパニー | 抗ミオスタチン抗体 |
WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
US8470332B2 (en) | 2006-11-22 | 2013-06-25 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
EP2111228B1 (en) | 2007-02-02 | 2011-07-20 | Bristol-Myers Squibb Company | 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis |
CA2840407A1 (en) * | 2007-05-22 | 2008-12-18 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
AU2008287426B2 (en) | 2007-08-10 | 2014-06-26 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
US8680019B2 (en) | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
JP2010538972A (ja) | 2007-08-20 | 2010-12-16 | ブリストル−マイヤーズ スクイブ カンパニー | 転移性癌の処置のためのvegfr−2阻害剤の使用 |
KR100857861B1 (ko) * | 2007-10-15 | 2008-09-11 | 주식회사 바이오리더스 | Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물 |
US8633297B2 (en) | 2007-10-31 | 2014-01-21 | Medimmune, Llc | Protein scaffolds |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
WO2009073115A1 (en) | 2007-11-28 | 2009-06-11 | Bristol-Myers Squibb Company | Combination vegfr2 therapy with mtor inhibitors |
EP2238247A2 (en) | 2007-12-19 | 2010-10-13 | Centocor Ortho Biotech Inc. | Alternative scaffold protein fusions phage display via fusion to plx of m13 phage |
US20100322930A1 (en) | 2007-12-27 | 2010-12-23 | Frank Kolbinger | Fibronectin-based binding molecules and their use |
EP2080812A1 (en) | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
MX2010008874A (es) | 2008-02-14 | 2010-09-22 | Bristol Myers Squibb Co | Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico. |
EP3173424A1 (en) | 2008-05-02 | 2017-05-31 | Novartis Ag | Improved fibronectin-based binding molecules and uses thereof |
CN102099373A (zh) | 2008-05-22 | 2011-06-15 | 百时美施贵宝公司 | 基于纤连蛋白的多价支架结构域蛋白 |
US8278419B2 (en) | 2008-10-31 | 2012-10-02 | Centocor Ortho Biotech Inc. | Fibronectin type III domain based scaffold compositions, methods and uses |
US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
ES2410579T5 (es) | 2008-12-16 | 2021-10-04 | Novartis Ag | Sistemas de despliegue de levaduras |
AR074777A1 (es) * | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
EP2396000A1 (en) | 2009-02-11 | 2011-12-21 | Bristol-Myers Squibb Company | Combination vegfr2 therapy with temozolomide |
DK2396011T3 (en) | 2009-02-12 | 2016-04-25 | Janssen Biotech Inc | Fibronectin TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, METHODS AND USES |
US8067201B2 (en) | 2009-04-17 | 2011-11-29 | Bristol-Myers Squibb Company | Methods for protein refolding |
EP2464663A4 (en) | 2009-08-13 | 2013-05-29 | Massachusetts Inst Technology | RECOMBINANT PROTEINS COMPRISING MUTANT DOMAINS OF FIBRONECTIN |
ES2691717T3 (es) | 2009-10-30 | 2018-11-28 | Novartis Ag | Bibliotecas universales del dominio de unión del lado inferior de tipo iii de la fibronectina de tipo III |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
US20110123545A1 (en) | 2009-11-24 | 2011-05-26 | Bristol-Myers Squibb Company | Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases |
WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
WO2011100700A2 (en) | 2010-02-12 | 2011-08-18 | University Of Rochester | Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies |
US8927693B2 (en) | 2010-02-18 | 2015-01-06 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind IL-23 |
UY33331A (es) * | 2010-04-13 | 2011-10-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Proteinas de dominio de armazon basadas en fibronectina que se unen a pcsk9 |
US20130079280A1 (en) | 2010-04-13 | 2013-03-28 | Medlmmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
BR112012027863B1 (pt) | 2010-04-30 | 2023-03-07 | Janssen Biotech, Inc | Polipeptídeos, arcabouços de proteína, bibliotecas e métodos de construção das mesmas, método para gerar uma ligação de arcabouço de proteína a um alvo específico com uma afinidade de ligação predefinida, moléculas de ácido nucleico isolada, vetores, células hospedeiras, composições, dispositivos médicos, e artigos de fabricação |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
EP3091028A1 (en) | 2010-05-26 | 2016-11-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
KR20130136443A (ko) | 2010-07-30 | 2013-12-12 | 노파르티스 아게 | 피브로넥틴 크레이들 분자 및 그의 라이브러리 |
CN105440134A (zh) | 2010-08-16 | 2016-03-30 | 安姆根公司 | 结合肌肉生长抑制素的抗体、组合物和方法 |
WO2012088006A1 (en) | 2010-12-22 | 2012-06-28 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind il-23 |
PT2697257T (pt) | 2011-04-13 | 2016-12-28 | Bristol Myers Squibb Co | Proteínas de fusão fc compreendendo novos ligantes ou arranjos |
US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
EP2710382B1 (en) | 2011-05-17 | 2017-10-18 | Bristol-Myers Squibb Company | Improved methods for the selection of binding proteins |
KR102142385B1 (ko) | 2011-09-27 | 2020-08-10 | 얀센 바이오테크 인코포레이티드 | 대체 결합 표면을 가진 피브로넥틴 유형 iii 반복체 기반의 단백질 스캐폴드 |
SG11201408228QA (en) | 2012-06-11 | 2015-01-29 | Amgen Inc | Dual receptor antagonistic antigen-binding proteins and uses thereof |
MX364738B (es) | 2012-06-15 | 2019-05-03 | Pfizer | Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos. |
CN104768969B (zh) | 2012-09-13 | 2021-04-16 | 百时美施贵宝公司 | 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白 |
TW201842929A (zh) | 2017-05-03 | 2018-12-16 | 美商必治妥美雅史谷比公司 | 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物 |
-
2013
- 2013-09-12 CN CN201380056757.6A patent/CN104768969B/zh active Active
- 2013-09-12 NZ NZ628446A patent/NZ628446A/en unknown
- 2013-09-12 MY MYPI2019003412A patent/MY189682A/en unknown
- 2013-09-12 SG SG10201701970TA patent/SG10201701970TA/en unknown
- 2013-09-12 TW TW102133033A patent/TWI633117B/zh active
- 2013-09-12 RS RS20210753A patent/RS62009B1/sr unknown
- 2013-09-12 IL IL270110A patent/IL270110B/en unknown
- 2013-09-12 EA EA201590543A patent/EA033536B1/ru not_active IP Right Cessation
- 2013-09-12 TW TW107106852A patent/TWI694085B/zh active
- 2013-09-12 MY MYPI2015700817A patent/MY172863A/en unknown
- 2013-09-12 DK DK13767190.5T patent/DK2895503T3/da active
- 2013-09-12 PT PT13767190T patent/PT2895503T/pt unknown
- 2013-09-12 EP EP19162848.6A patent/EP3564258B1/en active Active
- 2013-09-12 EP EP13767190.5A patent/EP2895503B1/en active Active
- 2013-09-12 MX MX2015002894A patent/MX366666B/es active IP Right Grant
- 2013-09-12 KR KR1020207034555A patent/KR102424590B1/ko active IP Right Grant
- 2013-09-12 SG SG10201913685YA patent/SG10201913685YA/en unknown
- 2013-09-12 JP JP2015532042A patent/JP6346895B2/ja active Active
- 2013-09-12 KR KR1020227025177A patent/KR20220107082A/ko not_active Application Discontinuation
- 2013-09-12 CN CN201810199962.2A patent/CN108409856B/zh active Active
- 2013-09-12 SG SG11201501741YA patent/SG11201501741YA/en unknown
- 2013-09-12 ES ES19162848T patent/ES2879387T3/es active Active
- 2013-09-12 DK DK19162848.6T patent/DK3564258T3/da active
- 2013-09-12 LT LTEP13767190.5T patent/LT2895503T/lt unknown
- 2013-09-12 UY UY0001035027A patent/UY35027A/es active IP Right Grant
- 2013-09-12 IL IL294314A patent/IL294314A/en unknown
- 2013-09-12 US US14/025,253 patent/US8933199B2/en active Active
- 2013-09-12 HU HUE19162848A patent/HUE054699T2/hu unknown
- 2013-09-12 KR KR1020157009067A patent/KR102187714B1/ko active IP Right Grant
- 2013-09-12 BR BR112015005466-8A patent/BR112015005466B1/pt active IP Right Grant
- 2013-09-12 PL PL19162848T patent/PL3564258T3/pl unknown
- 2013-09-12 LT LTEP19162848.6T patent/LT3564258T/lt unknown
- 2013-09-12 AU AU2013315482A patent/AU2013315482B2/en active Active
- 2013-09-12 US US14/025,307 patent/US8853154B2/en active Active
- 2013-09-12 WO PCT/US2013/059458 patent/WO2014043344A1/en active Application Filing
- 2013-09-12 LT LTEP20206702.1T patent/LT3835310T/lt unknown
- 2013-09-12 EP EP20206702.1A patent/EP3835310B1/en active Active
- 2013-09-12 PE PE2015000354A patent/PE20150954A1/es active IP Right Grant
- 2013-09-12 HU HUE13767190A patent/HUE043482T2/hu unknown
- 2013-09-12 SI SI201331889T patent/SI3564258T1/sl unknown
- 2013-09-12 CA CA2884730A patent/CA2884730C/en active Active
- 2013-09-12 PT PT191628486T patent/PT3564258T/pt unknown
- 2013-09-12 ES ES13767190T patent/ES2727453T3/es active Active
- 2013-09-12 RS RS20190618A patent/RS58801B1/sr unknown
- 2013-09-12 SI SI201331453T patent/SI2895503T1/sl unknown
- 2013-09-12 PL PL13767190T patent/PL2895503T3/pl unknown
-
2014
- 2014-05-12 US US14/275,542 patent/US8993265B2/en active Active
- 2014-09-09 US US14/481,641 patent/US9493546B2/en active Active
-
2015
- 2015-02-24 PH PH12015500397A patent/PH12015500397B1/en unknown
- 2015-02-26 US US14/632,436 patent/US9662373B2/en active Active
- 2015-02-27 CL CL2015000500A patent/CL2015000500A1/es unknown
- 2015-03-03 ZA ZA2015/01457A patent/ZA201501457B/en unknown
- 2015-03-04 IL IL23755915A patent/IL237559B/en active IP Right Grant
- 2015-03-05 MX MX2019008391A patent/MX2019008391A/es unknown
- 2015-03-06 TN TNP2015000086A patent/TN2015000086A1/fr unknown
-
2016
- 2016-01-21 HK HK16100687.0A patent/HK1212717A1/zh unknown
- 2016-09-30 US US15/282,277 patent/US10245302B2/en active Active
-
2017
- 2017-04-19 US US15/491,271 patent/US10406212B2/en active Active
-
2018
- 2018-02-22 AU AU2018201273A patent/AU2018201273B2/en active Active
- 2018-05-28 JP JP2018101646A patent/JP6793680B2/ja active Active
-
2019
- 2019-02-14 US US16/276,156 patent/US11813315B2/en active Active
- 2019-05-07 HR HRP20190845TT patent/HRP20190845T1/hr unknown
-
2021
- 2021-06-23 HR HRP20210990TT patent/HRP20210990T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212717A1 (zh) | 結合至肌生成抑制素的基於纖連蛋白的支架結構域蛋白 | |
HK1257028A1 (zh) | 可注射製劑 | |
ZA201408580B (en) | Detergent composition | |
HK1179276A1 (en) | Fibronectin based scaffold domain proteins that bind il-23 il-23 | |
ZA201500575B (en) | Adw detergent composition | |
PL2662436T3 (pl) | Kompozycja detergentu | |
SG11201504939RA (en) | Microcontroller | |
BR302013002335S1 (pt) | Configuração aplicada em porta-objetos | |
EP2861068A4 (en) | METHODS ASSOCIATED WITH BEVACIZUMAB | |
HK1204551A1 (en) | Injectable compositions | |
EP2856158A4 (en) | PROCEDURE RELATED TO RITUXIMAB | |
BR112015012440A2 (pt) | composição de limpeza | |
GB2507762B (en) | Improvements to dartboards | |
ZA201504070B (en) | Detergent composition | |
GB201215288D0 (en) | Improvements relating to firelighters | |
GB201206287D0 (en) | Bid to rent property | |
BR302012004065S1 (pt) | Configuração aplicada me recipiente anatômico | |
BR302012002575S1 (pt) | Configuração aplicada em caneca barril | |
GB201201142D0 (en) | Sdd |